Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 14/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 2/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286420 | 0.90 | ALDH1A1 (0.45) | NPBWR1MCHR1BRD4PKMPKLR | |
| SCHEMBL15130259 | 0.81 | NPBWR1 (0.45) | NPBWR1MCHR1UCHL1L3MBTL1 | |
| SCHEMBL370615 | 0.79 | NPBWR1 (0.44) | NPBWR1MCHR1UCHL1L3MBTL1 | |
| SCHEMBL12118244 | 0.78 | NPBWR1 (0.62) | NPBWR1MCHR1BRD4PKMPKLR | |
| SCHEMBL1311364 | 0.77 | NPBWR1 (0.57) | NPBWR1MCHR1BRD4PKMPKLR | |
| SCHEMBL15130283 | 0.76 | NPBWR1 (0.44) | NPBWR1MCHR1 | |
| SCHEMBL15130274 | 0.76 | NPBWR1 (0.39) | NPBWR1MCHR1PKMUCHL1L3MBTL1 | |
| SCHEMBL15130272 | 0.76 | NPBWR1 (0.39) | NPBWR1MCHR1PKMUCHL1L3MBTL1 | |
| SCHEMBL25345977 | 0.75 | NPBWR1 (0.55) | NPBWR1MCHR1BRD4PKMPKLR | |
| SCHEMBL1311733 | 0.75 | NPBWR1 (0.55) | NPBWR1MCHR1BRD4PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2334673-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2334674-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | Amgen, Inc (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025202-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025202-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | MAPK1, MAP3K1, MAP4K2 | NPBWR1 1251/4885MCHR1 2164/4885BRD4 1065/4885 |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | MAPK1, MAPK3, MAP4K2 | NPBWR1 795/4885MCHR1 2042/4885BRD4 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.